SCOTUS Preserves Mifepristone Access
The Supreme Court unanimously rejected a major challenge to the FDA's regulations for the abortion pill mifepristone on June 13, 2024, ensuring its continued nationwide availability. This 9-0 decision found that the anti-abortion doctors and medical associations lacked legal standing to sue, thus upholding the FDA's authority and averting a significant disruption to reproductive healthcare across the U.S.